首页> 外文期刊>Oncology letters >DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA.
【24h】

DNA methylation analysis of SFRP2, GATA4/5, NDRG4 and VIM for the detection of colorectal cancer in fecal DNA.

机译:SFRP2,GATA4 / 5,NDRG4和VIM的DNA甲基化分析,用于检测粪便DNA中的结直肠癌。

获取原文
获取原文并翻译 | 示例
           

摘要

Aberrantly methylated genes are increasingly being established as biomarkers for the detection of colorectal cancer (CRC). In the present study, the methylation levels of the secreted frizzled-related protein gene 2 (SFRP2), GATA binding protein 4/5 (GATA4/5), N-Myc downstream-regulated gene 4 (NDRG4) and vimentin (VIM) promoters were evaluated for their use as markers in the noninvasive detection of CRC. Methylation-specific polymerase chain reaction was performed to analyze promoter CpG methylation of SFRP2, GATA4/5, NDRG4 and VIM in the fecal DNA of 56 patients with CRC and 40 individuals exhibiting normal colonoscopy results. Promoter methylation levels of SFRP2, GATA4/5, NDRG4 and VIM in CRC patients were 57.1% (32/56), 42.9% (24/56), 83.9% (47/56), 28.6% (16/56) and 41.1% (23/56), respectively. Furthermore, the specificity of the genes were 90.0% (4/40), 95.0% (2/40), 82.5% (7/40), 97.5% (4/40) and 85.0% (6/40), respectively. The overall sensitivity of detection for fecal DNA with at least one methylated gene was 96.4% (54/56) in CRC patients. By contrast, only 14 of the 40 normal individuals exhibited methylated DNA in the aforementioned promoter regions. Methylation of the SFRP2, GATA4/5, NDRG4 and VIM promoters in fecal DNA is associated with the presence of colorectal tumors. Therefore, the detection of aberrantly methylated DNA in fecal samples may present a promising, noninvasive screening method for CRC.
机译:越来越多地将异常甲基化的基因建立为用于检测结直肠癌(CRC)的生物标记。在本研究中,分泌的卷曲相关蛋白基因2(SFRP2),GATA结合蛋白4/5(GATA4 / 5),N-Myc下游调节基因4(NDRG4)和波形蛋白(VIM)启动子的甲基化水平评估了它们在CRC非侵入性检测中用作标记的用途。进行了甲基化特异性聚合酶链反应,以分析56例CRC患者和40例结肠镜检查结果正常的人粪便DNA中SFRP2,GATA4 / 5,NDRG4和VIM的启动子CpG甲基化。 CRC患者的SFRP2,GATA4 / 5,NDRG4和VIM的启动子甲基化水平分别为57.1%(32/56),42.9%(24/56),83.9%(47/56),28.6%(16/56)和41.1 %(23/56)。此外,基因的特异性分别为90.0%(4/40),95.0%(2/40),82.5%(7/40),97.5%(4/40)和85.0%(6/40)。 CRC患者中检测至少具有一个甲基化基因的粪便DNA的总体敏感性为96.4%(54/56)。相反,在40个正常个体中,只有14个在上述启动子区域显示甲基化DNA。粪便DNA中SFRP2,GATA4 / 5,NDRG4和VIM启动子的甲基化与结直肠肿瘤的存在有关。因此,粪便样品中异常甲基化DNA的检测可能为CRC提供一种有前途的,非侵入性的筛选方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号